The core purpose of the Value and Evidence Strategy team at Alnylam is to lead evidence generation and value demonstration activities through cross-functional collaboration with Clinical Development, Market Access, Market Insights, Regulatory Affairs, and other expertise areas. The Fellow will gain a thorough understanding of and hands on experience in health economics and outcomes research methodologies to scientifically evaluate a therapeutic’s potential economic, clinical, and humanistic impact. VESt’s goal is to ensure excellence in evidence generation so Alnylam’s innovative science can reach patients and healthcare systems.
About the Fellowship Program
Three years ago, Alnylam Pharmaceuticals partnered with Northeastern University to become the first Fellowship Program at a pre-commercial company. Since its inception, the Program has grown and continues to be an integral asset to all stakeholders. For the 2018 – 2020 recruitment cycle, the Fellowship Program is pleased to offer four 2-year positions in the following expertise areas: Regulatory Affairs, Medical Affairs, Value and Evidence Strategy (VESt)/HEOR, and Medical Information. The first year, Fellows customize their experience with individualized elective rotations throughout various groups at Alnylam while remaining a vital member in their core expertise area. In the second year, Fellows focus on their primary function. Throughout the two years, Fellows also have responsibilities at Northeastern University, such as teaching PharmD students and participating in longitudinal research with faculty.
We are always looking for curious and driven candidates! If you would like to receive updates from us, click here to sign up.
About Alnylam Pharmaceuticals in partnership with Northeastern University
Founded in 2002, Alnylam Pharmaceuticals established an unwavering commitment to
harnessing the power of RNA interference (RNAi) for treating rare conditions with high unmet
medical need. Today, it is leading the translation of RNAi to a novel class of innovative medicines
used to treat a wide range of diseases using its powerful, clinically validated approach. In
January 2015, the company mar...ked its transition from a scientifically driven company to a
patient-focused commercial enterprise. By launching the “Alnylam 2020” guidance for the
advancement and commercialization of RNAi therapeutics in three Strategic Areas (STArs):
Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases, the late-stage
clinical development company is poised to launch multiple commercial products, revolutionizing
patient care around the world.
Northeastern University is a global, experiential, research university built on a tradition of
engagement with the world, creating a distinctive approach to education and research. The
School of Pharmacy is dedicated to excellence in pharmacy-related education, research, and
service, including the provision of patient care. The Alnylam Pharmaceuticals and Northeastern
University Fellowship Program provides a dynamic academic environment to guide and
support Fellows toward successful careers in the biopharmaceutical industry and offers them
the opportunity to gain a wide range of large group didactic and small group practice-related teaching experiences
We are always looking for curious and driven candidates! If you would like to receive updates from us, click here to sign up - http://bit.ly/ALNY_CIF.